Ellipses Pharma Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
32
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$151M
- Investors
-
4
Ellipses Pharma General Information
Description
Developer of cancer medicines and treatments designed to make drugs and therapies available to patients at unprecedented speed. The company focuses on the advancement of cancer treatments through the clinic making more treatments available to patients, enabling clients to seek benefits for treating cancer diseases.
Contact Information
Website
www.ellipses.lifeCorporate Office
- 10 Stratton Street
- London W1J 8LG
- England, United Kingdom
Corporate Office
- 10 Stratton Street
- London W1J 8LG
- England, United Kingdom
Ellipses Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC | 11-Jul-2023 | $151M | Completed | Clinical Trials - General |
Ellipses Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 7,672,400 | $0.001272 | $2.54 | $2.54 | 1x | $2.54 | 6.27% | |
| Ordinary | 37,116,434 | $0.001272 | $0.95 | $0.95 | 1x | $0.95 | 30.35% |
Ellipses Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ellipses Pharma Patents
Ellipses Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202416269-D0 | Compounds for treatmant of cancers | Inactive | 04-Nov-2024 | ||
| WO-2026018023-A1 | Synergistic combinations comprising lunbotinib for anti-cancer therapy | Pending | 19-Jul-2024 | ||
| GB-202410599-D0 | Therapeutics useful synergistic combinations | Pending | 19-Jul-2024 | ||
| WO-2026017996-A1 | Combinations of cct241736 and venetoclax, or of cct241736, venetoclax and azacitidine for use in the treatment of cancer | Pending | 16-Jul-2024 | ||
| GB-202410375-D0 | Compounds for treatment of cancers | Inactive | 16-Jul-2024 |
Ellipses Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ellipses Pharma Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| West Coast Capital | Family Office | Minority |
Ellipses Pharma FAQs
-
When was Ellipses Pharma founded?
Ellipses Pharma was founded in 2015.
-
Where is Ellipses Pharma headquartered?
Ellipses Pharma is headquartered in London, United Kingdom.
-
What is the size of Ellipses Pharma?
Ellipses Pharma has 32 total employees.
-
What industry is Ellipses Pharma in?
Ellipses Pharma’s primary industry is Drug Discovery.
-
Is Ellipses Pharma a private or public company?
Ellipses Pharma is a Private company.
-
What is the current valuation of Ellipses Pharma?
The current valuation of Ellipses Pharma is .
-
What is Ellipses Pharma’s current revenue?
The current revenue for Ellipses Pharma is .
-
How much funding has Ellipses Pharma raised over time?
Ellipses Pharma has raised $151M.
-
Who are Ellipses Pharma’s investors?
, , , and West Coast Capital have invested in Ellipses Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
